Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon On Track To File Treanda For Second Cancer Indication By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

Bendamustine meets both primary endpoints in Phase III for relapsed, rituximab-refractory non-Hodgkin’s lymphoma.

You may also be interested in...



Cephalon Files Treanda For NHL Indication

Chemotherapeutic has been granted a priority review for an earlier filing, for treatment of chronic lymphocytic leukemia.

Cephalon Files Treanda For NHL Indication

Chemotherapeutic has been granted a priority review for an earlier filing, for treatment of chronic lymphocytic leukemia.

Cephalon Files Treanda For Chronic Lymphocytic Leukemia

Submission represents a milestone for Cephalon’s oncology program, firm says.

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel